







WELCOME AND COMMITTEES

PROGRAMME

ABSTRACTS
AND PROCEEDINGS

REGISTRATION AND ACCOMMODATION

GENERAL INFORMATION

BURSARIES

POSTER PRIZE SPONSORS
AND EXHIBITORS

VIDEO CONTEST

Q

C2P2: Cells, Culture, Patients, Products

Programme

Information on

Workshops!!

SUNDAY 31st MAY

09.00 Registration opens

11.30-13.00 Topical Workshops (in parallel)

Final Scientific

Program

Available

• Single-cell analysis – A new tool for bioprocess engineering

(Level 2 - Room 3)

• From Glycoscience to Glycobiotechnology (Level 3 - Room 5)

Synthetic biology: New tools for engineering

mammalian cells

etic biology: New tools for engineering

(Level 3 - Room 6)

13.00-14.00 Lunch break (level 3 - Hall)

Important

Dates

Abstract submission: December 10th

2014

Early registration Deadline: March 30th 2015

14.00-15.30 Company Workshops (in parallel)

Meeting: May 31st 2015

 Thermo Fisher Scientific: CELL CULTURE: "High Octane Fed-Batch: Process Intensification Reimagined" and SINGLE-USE TECHNOLOGY: "Innovative Single Use Technologies for Biopharma Processes"

(Level 2 - Room 3)

 Sartorius Stedim Biotech: Innovation in Cell Culture Technology

(Level 3 - Room 5)

 SAFC: Applying an integrated design approach to create a novel high performance fed-batch media system for mammalian cells (Level 3 - Room 6)

16.00-17.30 Opening & KeyNote (Auditorium)

Chairperson: Martin Fussenegger

 Biological Functions and Therapeutic Potential of Vascular Endothelial Growth Factors
 Kari Alitalo (Translational Cancer Biology Program and Wihuri Research Institute, Biomedicum Helsinki, Finland)

17.30-19.00 Session 1: Cell line engineering (Auditorium)

Chairpersons: Hitto Kaufmann and Hansjörg Hauser

- 17.30-18.00. Front-line of genome editing technology for animal cell engineering Tetsushi Sakuma (Hiroshima University, Japan)
- 18.00-18.20. Efficient genome engineering of CHO cell factories using CRISPR Cas9 technology
 Helene Faustrup Kildegaard (Technical University of Denmark, Denmark)
- 18.20-18.40. Optimization of protein production via genetic engineering of CHO cell line Pierre-Alain Girod (Selexis, Switzerland)
- 18.40-19.00. Enabling tools for virus producer cell line development and engineering Ana Sofia Coroadinha (IBET, Portugal)

19.00-21.00 Traders Reception (Level 0 - Exhibiton area)

MONDAT 1st JUNE

* Sponsors

If you are interested in collaborating, please contact here

DIAMOND SPONSORS







09.00-10.30 Session 1: Cell line engineering (Auditorium)

Chairpersons: Hitto Kaufmann and Hansjörg Hauser

 09.00-09.30. C/EBP a creates an elite cell state in B cells

Thomas Graf (Center of Genomic Regulation, Spain)

• 09.30-09.50. Adventitious agent contamination risk mitigation: engineering mmv virus resistance into the chozn® platform

Joaquina Mascarenhas (Sigma Aldrich, USA)

- 09.50-10.10. Finding the needle(s) in the haystack: identification of mirna master regulators improving productivity independent of cell type and product Simon Fischer (University of Applied Sciences Biberach, Germany)
- 10.10.10.30. Production of IgGs with a human-like sialylation in CHO cells. Céline Raymond (National Research Council of Canada, Canada)

10.30-11.00 Coffee break (Level 0 - Exhibition area)

11.00-13.00 Session 2: Cell based assays to drive drug development (Auditorium)

Chairpersons: Manuel Reina and Christa Burger

- 11.00-11.30. Cell-based methods for early detection of hepatotoxicity in drug development: high content multiparametric screening and toxico-metabolomics José Vicente Castell (Hospital La Fe, Spain)
- 11.30-12.00. Novel iPSC-derived cellular systems for in vitro disease modeling.

Giorgia Salvagiotto (Cellular Dynamics, USA)

- 12.00-12.15. Next-generation 96-well tissue culture plates re-engineered via 3D printing: A screening platform for measuring contractile force in human pluripotent stem cell-derived cardiac microtissues. Nimalan Thavandiran (University of Toronto, Canada)
- 12.15-12.30. A "Human-on-a-Chip" platform-aiming for a paradigm shift in substance testing Uwe Marx (TissUse Berlin, Germany)
- 12.30-12.45. Metabolic profiling of human neural cells: combining 3d in vitro models and 13c-nmr spectroscopy.

Daniel Simão (IBET, Portugal)

• 12.45-13.00. Immortalized lung epithelial cells with in vivo like characteristics.

Tobias May (InSCREENeX GmbH, Germany)

13.00-14.30 Lunch break (Level 2 - Restaurant)

14.30-16.00 Poster session and coffee (Level 1 and 0) Presenting authors must be at their poster for discussion

16.00-17.30 Session 3: Linking process engineering to product quality (Auditorium)

Chairpersons: Ashraf Amanullah and Alain Bernard

- 16.00-16.30. The beauty and the beast: a perspective on Biopharmaceuticals.
 Ralf Otto (McKinsey and Co, Germany)
- 16.30-16.50. Improved production and quality of enveloped viral particles in BEVS: a host cell-driven and target-oriented approach.

Francisca Monteiro (IBET, Portugal)

 16.50-17.10. Identification of process parameters influencing product quality in mammalian cell culture.

Albert Paul (Biberach University of Applied Sciences, Germany)

 17.10-17.30. Non-fucose level as a function of glycoenzyme transcription in a glycoengineered cho cell line.

Sven Markert (Roche Diagnostics GmbH, Germany)

18.00-22.00 Sagrada Família + Hospital Sant Pau + Cocktail

TUESDAY 2nd JUNE

09.00-10.30 Session 3: Linking process engineering to product quality (Auditorium)

Chairpersons: Ashraf Amanullah and Alain Bernard

 09.00-09.30. When Bad Things Happen to Good Proteins: Effects of Cell Culture Process on Protein Characteristics

Robert Kiss (Genentech, USA)

- 09.30-09.50. Understanding the impact of mild hypothermia on monoclonal antibody glycosylation in cho cell cultures.
 - Si Nga Sou (Imperial College London, UK)
- 09.50-10.10. Dynamic flux analysis of GS-CHO cells: Identifying the burden of protein glycosylation on cellular metabolism.
 - loscani Jiménez Del Val (University College Dublin, Ireland)
- 10.10-10.30. Process parameters impacting product quality

Jan Bechmann (Boehringer Ingelheim Pharma GmbH & Co. KG, Germany)

10.30-11.00 Coffee break (Level 0 - Exhibition area)

11.00-13.10 Session 4: Emerging technologies (Auditorium)

Chairpersons: Martin Fussenegger and Ana Filipa Rodrigues

- 11.00-11.40. Targeting cancer and chronic inflammation with armed antibodies and small molecule drug conjugates
 Dario Neri (ETH Zurich, Switzerland)
- 11.40-12.10. Complex primary cell-based models for drug discovery
 Heinz Ruffner (Novartis Institute of Biomedical Research, Switzerland)
- 12.10-12.25. DNA methylation in CHO dp-12 cells: landscape and effects on gene expression
 Ana Wippermann (Bielefeld University, Germany)
- 12.25-12.40. High-Density 3D Cell Culture and Analysis in an Integrated Microfluidic Platform Sebastien Sart (Ecole Polytechnique LADHYX, France)
- 12.40-12.55. Mammalian designer cells for biomedical applications
 David Ausländer (ETH Zürich Basel, Switzerland)
- 12.55-13.10. Multi-omics approach for comparative studies of monoclonal antibody producing cho cells Camila A. Orellana (AIBN, The University of Queensland, Australia)
- 13.10-14.30 Esact General Assembly (Lunch provided) (Room 5)
- 13.10-14.30 Lunch break (Level 2 Restaurant)
- 14.30-16.00 Poster session and coffee (Level 1 and 0)
 Presenting authors must be at their poster for discussion.
 From 14.30 to 15.15 for even poster numbers and from 15.15 to 16.00 for uneven numbers
- 16.00-17.30 Session 5: New Therapeutic Approaches (Auditorium)

Chairpersons: Terry Papoutsakis and Margarida Serra

- 16.00-16.30. Antibody-drug conjugates: implications on the design of mAbs
 Aad van de Leur (Synthon Biopharmaceuticals, The
 - Aad van de Leur (Synthon Biopharmaceuticals, The Netherlands)
- 16.30-16.50. Expression and manufacture of a new bispecific drug for her2+breast cancer: the beat-gbr 1302 antibody
 - Pierre Moretti (Glenmark Pharmaceuticals, Switzerland)
- 16.50-17.10. Development of an advanced cell therapy product indicated for the treatment of gonarthrosis
 - Joaquim Vives (Banc de Sang I Teixits, Spain)
- 17.10-17.30. Optimization of hpsc production from distinct pluripotent and metabolic states Yonatan Lipsitz (University of Toronto, Canada)

WEDNESDAY 3rd JUNE

09.00-10.30 Session 5: New Therapeutic Approaches (Auditorium)

Chairpersons: Terry Papoutsakis and Margarida Serra

 09.00-09.40. AVV at 50: A golden anniversary of discovery research, and gene therpay success in the Samulski lab

R. Jude Samulski (U. North Carolina, USA)

 09.40-10.10. Rapid Response Ebola Antibody Development Enabled by High Throughput Technologies

Kevin Bailey (Regeneron, USA)

 10.10-10.30. Protein aerosol for intranasal nose to brain (N2B) delivery
 Martina Stuetzle (University of applied Sciences Biberach, Germany)

10.30-11.00 Coffee break (Level 0 - Exhibition area)

11.00-13.00 Session 6: Cell based Vaccines (Auditorium)

Chairpersons: Amine Kamen and Yvonne Genzle (porposed)

• 11.00-11.30. Recombinant vaccine made in Insect cells

Mannon Cox (Protein Sciences, USA)

- 11.30-12.00. Fighting Ebola Virus infection: the Development and Use of Ebola Monoclonal Antibodies and Vaccines Xiangguo Qiu (Public Health Agency, Canada)
- 12.00-12.20. Development of an anti-idiotypic Mab as cancer vaccine: from discovery to approval Adolfo Castillo (Center of Molecular Immunology, Cuba)
- 12.20-12.40. Development of a mammalian cell culture process for the rapid clinical-scale production of novel influenza nanoparticle vaccines Payal Biswas (VPP-VRC-NIAID-NIH, USA)
- 12.40-13.00. Purification of Modified Vaccinia Virus Ankara from suspension cell culture Ingo Jordan (ProBioGen AG, Germany)

13.00-14.30 Lunch (Level 2 - Restaurant)

14.30-16.00 Poster session: presentation of posters selected for poster prize (Auditorium)

Chairpersons: Mercedes Segura and Verena Lohr

16.00-17.30 Keynote + Closing

Chairperson: Hansjörg Hauser

• Gene Therapy of Inherited Muscle Diseases Fulvio Mavilio (Genethon, France)

21.00-24.00 Gala Dinner at MNAC

^



Web site created by **GRUPOPACIFICO**The power of meeting